SPOTLIGHT -
EP. 1: Introduction and Exploration of Fulvestrant in Breast Cancer
EP. 2: Combination of Anastrozole and Fulvestrant in MBC
EP. 3: BOLERO-2 Trial: Everolimus in Metastatic Breast Cancer
EP. 4: Management of mTOR Inhibitor Side Effects in Breast Cancer
EP. 5: EMILIA Trial: T-DM1 in Metastatic Breast Cancer
EP. 6: Frontline T-DM1 in HER2+ Metastatic Breast Cancer
EP. 7: CLEOPATRA Trial: Frontline Pertuzumab for HER2+ MBC
EP. 8: MA.31 Trial: Taxane With Lapatinib or Trastuzumab
EP. 9: Treatment With Eribulin in Metastatic Breast Cancer
EP. 10: Case Study: Treating HER2-Positive MBC, Part I
EP. 11: Case Study: Treating HER2-Positive MBC, Part II
EP. 12: Paclitaxel With Pertuzumab Plus Trastuzumab in MBC
EP. 13: Case Study: Treating HR+ and HER2- Breast Cancer
EP. 14: Managing Bone Health in Metastatic Breast Cancer
EP. 15: Surgical Removal of Primary Tumors in Stage IV MBC
EP. 16: Case Study: Metastatic Triple-Negative Breast Cancer
EP. 17: Personalized Medicine in Triple-Negative Breast Cancer
EP. 18: Conclusion and Final Thoughts on Managing Breast Cancer
Up-Front Osimertinib Provides Comparable OS, Improved Brain PFS Vs Sequential Gefitinib/Osimertinib in EGFR+ NSCLC
Dr Nasioudis on the Use of NGS to Identify the Molecular Profile of Endometroid Ovarian Cancer
Dr Buckingham on the Use of Patient-reported Outcomes to Predict Frailty in Patients With Ovarian Cancer
Dr Slomovitz on the Investigation of Letrozole Plus Ribociclib in Low-Grade Serous Ovarian Carcinoma
